MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

acute ischemic stroke

  • Home
  • acute ischemic stroke
  • Page 2
Edaravone Dexborneol in Acute Ischemic Stroke: Real-World Evidence of Enhanced Functional Recovery and Safety
Posted inClinical Updates Neurology news Specialties

Edaravone Dexborneol in Acute Ischemic Stroke: Real-World Evidence of Enhanced Functional Recovery and Safety

Posted by By MedXY 08/17/2025
In a large multicenter cohort study, edaravone dexborneol treatment in acute ischemic stroke patients was linked to improved 90-day functional outcomes without increased adverse events, supporting its clinical utility.
Read More
JAMA: Extending Intravenous Alteplase to 24 Hours in Imaging‑Selected Ischemic Stroke (HOPE Trial)
Posted inClinical Updates Neurology news Specialties

JAMA: Extending Intravenous Alteplase to 24 Hours in Imaging‑Selected Ischemic Stroke (HOPE Trial)

Posted by By MedXY 08/10/2025
The HOPE randomized trial shows that CT‑perfusion–selected patients treated with intravenous alteplase at 4.5–24 hours (no planned thrombectomy) had higher 90‑day functional independence (40.3% vs 26.3%), with increased symptomatic intracranial hemorrhage but no higher mortality.
Read More

Posts pagination

Previous page 1 2
  • Enhanced Risk Stratification for Pediatric Tracheostomy Hospitalizations: Evaluating a Novel Tracheostomy-Specific Tier System
  • Long-Term Outcomes of Dysphagia Following Type I Laryngeal Cleft Repair in Children
  • Inadvertent Parathyroidectomy During Thyroid Surgery: Incidence, Risk Factors, and Clinical Implications
  • Understanding Surgical Faculty Retention: Key Factors Influencing Their Decision to Stay or Leave
  • Sustained Benefits of a Multidomain Lifestyle Intervention in Multiple Sclerosis: Insights from the 24-Month LIMS Study Follow-Up
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top